ASCO 2020 Virtual Annual Meeting, Lung Cancer
ASCO Lung Cancer Conference Reportv2.indd Download PDF Phase 3 CASPIAN Trial Update: Results &...
Read More
ASCO 2020
Chemoimmunotherapy: Efficacy Among Small Cell Lung Cancer Patients
“The overall take home message from the Virtual ASCO Annual Meeting this year is that...
Read MorePhase II Keynote-799 Offers Promise for Stage IIA-C NSCLC
Results from the phase 2 Keynote-799 trial show that addition of pembrolizumab to concurrent chemoradiation in patients with unresectable, stage IIIA-C NSCLC leads to objective response rates (ORR) that exceeded 50%, researchers...
Read More
Atezolizumab with SABR May Be Feasible for Early State NSCLC
Phase 1 trial shows feasibility and safety of neoadjuvant and adjuvant atezolizumab with...
Read More
Adding Pembrolizumab to Concurrent Neoadjuvant Chemoradiation in Stage IIIA Patients with NSCLC
Long-term outcomes are still poor for patients with locally advanced NSCLC with about 60% of the...
Read More
MET antibody mixture Sym015 is safe and demonstrates clinical activity in NSCLC
MET-mutations and MET-amplifications are reported in 1-6% of patients with NSCLC. In a phase 2...
Read More
Phase III ADAURA Trial: Practice Changing Results for NSCLC
Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit...
Read More
New Immunotherapy Treatment Promising for NSCLC
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being...
Read More
MET Mutation Inhibitor Associated with Tumor Reductions in NSCLC
Targeting tumor driver appears effective in half of NSCLC patients Treatment with the...
Read More